You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Showing    refined by:  

  • AREXVY ▼ Respiratory syncytial virus (RSV) vaccine (recombinant, adjuvanted)

    AREXVY patient information for members of the UK public

  • Ambirix vaccine | GSK public

    Information on Ambirix vaccine for members of public including summary of product characteristics and patient information leaflet

  • Bexsero I GSK Public

    Information on Bexsero vaccine for members of public including summary of product characteristics and patient information leaflet.

  • Boostrix-IPV

    Information on Boostrix-IPV (diphtheria, tetanus, pertussis (acellular) and poliomyelitis (inactivated)) for members of public including summary of product characteristics and patient information leaflet

  • Dectova ▼

    Information on Dectova▼(zanamivir hydrate) for members of public including summary of product characteristics and patient information leaflet

  • Engerix B vaccine | GSK public

    Information on Engerix B vaccine for members of public including summary of product characteristics and patient information leaflet

  • Engerix B Paediatrics vaccine | GSK public

    Information on Engerix B Paediatrics vaccine for members of public including summary of product characteristics and patient information leaflet

  • Fendrix vaccine | GSK public

    Information on Fendrix vaccine for members of public including summary of product characteristics and patient information leaflet

  • Havrix Junior Monodose vaccine | GSK Public

    Information on Havrix Junior Monodose vaccine for members of public including summary of product characteristics and patient information leaflet

  • Havrix Monodose vaccine | GSK public

    Information on Havrix Monodose vaccine for members of public including summary of product characteristics and patient information leaflet

  • Infanrix-IPV+Hib

    Information on Infanrix-IPV+Hib (Diptheria, tetanus, pertussis (acellular), poliomyelitis (inactivated) and Haemophilus influenzae type b conjugate vaccine adsorbed)) for members of public including summary of product characteristics and patient information leaflet

  • MOP | SHINGRIX landing page

    SHINGRIX patient information for members of the UK public

  • Menitorix

    Information on Menitorix (hib, meningococcal group c combined vaccine) for members of public including summary of product characteristics and patient information leaflet

  • Menveo vaccine | GSK public

    Information on Menveo vaccine for members of public including summary of product characteristics and patient information leaflet

  • Omjjara ▼ (momelotinib)

    Omjjara ▼ (momelotinib) | Information for members of the public

  • Priorix

    Information on Priorix (Measles, Mumps and Rubella vaccine (live)) for members of public including summary of product characteristics and patient information leaflet

  • Relenza

    Information on Relenza (zanamivir) for members of public including summary of product characteristics and patient information leaflet

  • Rotarix

    Information on Rotarix (live attenuated rotavirus vaccine) for members of public including summary of product characteristics and patient information leaflet

  • Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol)

    Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) product information for the UK members of the public

  • Twinrix Adult Vaccine | GSK public

    Information on Twinrix vaccine for members of public including summary of product characteristics and patient information leaflet

  • Twinrix Paediatrics vaccine | GSK public

    Information on Twinrix Paediatrics vaccine for members of public including summary of product characteristics and patient information leaflet

  • Varilrix

    Information on Varilrix (live attenuated varicella-zoster (Oka strain) virus) for members of public including summary of product characteristics and patient information leaflet

  • Zejula (niraparib)

    Information for members of public on Zejula (niraparib)

  • ▼ JEMPERLI (dostarlimab)

    ▼JEMPERLI (dostarlimab) information for UK members of the public.

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

There are no results matching your refine settings

Show more

Other products

Content is provided on this website for products with a United Kingdom product licence. In some cases, content may be provided relating to products that have mutual recognition or national licence, which has been created for United Kingdom audiences.

For safety and patient information relating to products not currently listed, please refer to the electronic Medicines Compendium website.

Reporting of side effects. If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at https://yellowcard.mhra.gov.uk/. By reporting side effects you can help provide more information on the safety of this medicine.

Additional note for medicines / vaccines with a black triangle:

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See information in paragraph above to see how to report side effects.